
|Articles|December 18, 2013
- Melanoma (Issue 1)
- Volume 1
- Issue 1
The Outlook for BRAF Inhibitors in Melanoma
Author(s)Antoni Ribas, MD, PhD
Antoni Ribas, MD, PhD, professor of medicine, Jonsson Comprehensive Cancer Center, University of California, Los Angeles, discusses the outlook for BRAF inhibitors in melanoma.
Advertisement
Antoni Ribas, MD, PhD, professor of medicine, Jonsson Comprehensive Cancer Center, University of California, Los Angeles, discusses the outlook for BRAF inhibitors in melanoma.
Read more about BRAF inhibitors for the treatment of melanoma and
Articles in this issue
almost 12 years ago
Two BRAF Fusions Discovered in Some Pan-Negative Melanomasalmost 12 years ago
Understanding the Biologic Pathways in Basal Cell Carcinomaalmost 12 years ago
Advances in Metastatic Melanomaalmost 12 years ago
Targeted Therapies in Basal Cell Carcinomaalmost 12 years ago
The Treatment of Melanoma With Emerging Targeted TherapiesAdvertisement
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
FDA Grants Traditional Approval to Pirtobrutinib in CLL/SLL
2
Durable Responses With Novel Cell Therapy TARA-002 in BCG-Naive NMIBC
3
JANX007 Shows Promising Efficacy, Safety in Phase 1 Trial Update
4
LP-184 Demonstrates Favorable Efficacy and Safety in Advanced Solid Tumors
5







































